samedan logo

 
 
spacer
home > pmps > spring 2019 > a toxic conversation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Toxic Conversation

A cleanroom is one of the biggest single investments any business is likely to make. There are many great reasons why companies literally cannot afford to get it wrong, so it makes sense to ensure it is kept operational for as long as possible. The fact of the matter is that overspecifying on sterilisation could well be increasing the lifetime cost of cleanrooms through the wholly avoidable degradation of furniture and equipment.

All fixtures and fittings in cleanrooms must facilitate Good Manufacturing Practice, meaning that materials from which they are constructed need to be chemically inert. It should also be tough enough to withstand the regular sterilisation, which is why austenitic stainless steel has always been such a common feature in cleanroom design. Furniture and other equipment built from this material will maintain its structural integrity for decades, not years. However, this is only the case when it is looked after properly, which means matching it to the chosen sterilisation option and also ensuring it is not at risk from detergents and disinfectants.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sue Springett is Commercial Manager at Teknomek, which produces hygienic furniture and equipment. Having previously held similar positions in manufacturing and service industries, she has helped Teknomek introduce a series of new products specifically for cleanroom users.
spacer
Sue Springett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Quanticate Makes Key Appointment to Bolster Leadership Team

Hitchin, UK, 9TH JANUARY Quanticate, a global data-focused clinical research organisation (CRO), has announced the appointment of Yolanda Barbachano as Head of Statistics.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement